March 22, 2010
New sub-group analysis from the landmark RE-LY study has shown dabigatran etexilate significantly reduces the risk of stroke compared to warfarin irrespective of a patient’s risk profile for stroke.
Log in or Register now.
Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.